María Jesús García-Granda

Universidad Publica de Navarra — Spain

Medicine · Health Sciences

7h-index776citations11works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(11), Immunotherapy and Immune Responses(5), CAR-T cell therapy research(5), Immune Cell Function and Interaction(2), Immune cells in cancer(2)

Publications11 total

PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers
2023· 1 citedOpen Access
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
British Journal of Cancer·2021· 17 citedOpen Access
17P PD-1 and LAG-3 immune checkpoints constitutive activators exhibit differential expression phenotypes
Annals of Oncology·2021
Abstract 930: CB213: A half-life extended bispecific Humabody VH delivering dual checkpoint blockade to reverse the dysfunction of LAG3+PD-1+ double-positive T cells
Cancer Research·2020· 10 cited
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Frontiers in Pharmacology·2020· 83 citedOpen Access
A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Annals of Oncology·2019Open Access
Functional systemic <scp>CD</scp> 4 immunity is required for clinical responses to <scp>PD</scp> ‐L1/ <scp>PD</scp> ‐1 blockade therapy
EMBO Molecular Medicine·2019· 211 citedOpen Access
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
International Journal of Molecular Sciences·2019· 74 citedOpen Access
Functional systemic CD4 immunity is a differential factor for clinical responses to PD-L1/PD-1 blockade therapy in lung cancer
2018· 3 citedOpen Access
The intracellular signalosome of PD-L1 in cancer cells
Signal Transduction and Targeted Therapy·2018· 277 citedOpen Access
Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles
Biomaterials·2018· 100 citedOpen Access

Frequent Co-authors

David Escors(11), Hugo Arasanz(10), Grazyna Kochan(10), Ana Bocanegra(10), Miren Zuazo(9), Ruth Vera(7), María Gato(5), G. Fernández-Hinojal(5), Lucía Teijeira(4), Luisa Chocarro(4), Idoia Morilla(3), María José Lecumberri(3), Ángela Fernández de Lascoiti(3), Ruth Vera(3), Carolyn Edwards(3), James Legg(3), Maite Martínez(2), Berta Hernández(2), Carlos Hernández(2), Gonzalo Fernández(2)